MARKET RESEARCH TREND

OVERVIEW OF THE PHARMACEUTICAL MARKET IN IRAQ Years of underinvestment have taken their toll on the Iraqi healthcare market, as have international sanctions and deterioration of healthcare infrastructure due to war. Still an unpopular figure on the international market, Iraq\'s trade partners are few and far between - although Iraq does have a strong bargaining chip: its oil resources. Healthcare facilities are gradually improving, with plans for new hospitals such as two specialist hospitals planned in partnership with Iran\'sRed Crescent organisation. But access to funding is limited, import and exports are restricted, and the country has a severe shortage of trained medical professionals. As such, it is of little surprise that there are few distinctions in the market between OTC and prescription drugs, and counterfeit medicines are rife. Headline Expenditure Projections Pharmaceuticals : IQD1,239bn (US$1.06mn) in 2011 to IQD1,476bn (US$1.26bn) in 2012; +

THE PHARMACEUTICAL MARKET OF LITHUANIA - REVIEW We continue to hold our subdued outlook for the Lithuanian pharmaceuticals market during the next few years, on account of the changing economic and demographic situation. We expect limited low single digit growth in 2012 , with the market expected to increase by a local currency margin of 2.5% year-on-year (y-o-y) to reach LTL1.6 8 bn (US$6 18 mn) in 2012 at consumer prices. However, in US dollar terms, the market \' s value will shrink by 6.3%, in dicating the challenges facing companies operating in the market . Headline Expenditure Projections Pharmaceuticals: LTL1.64bn (US$659mn) in 2011 to LTL1.68bn (US$618mn) in 2012; +2.5% in local currency terms and -6.3% in US dollar terms. Forecastslightly upfrom Q4 12on account of new macroeconomic data. Healthcare: LTL6.99bn (US$2.81bn) in 2011 to LTL7.29bn (US$2.68bn) in 2012; +4.3% in local currency terms and -4.7% in US dollar terms. Forecast slightly up fro

OVERVIEW OF THE PHARMACEUTICAL MARKET IN SAUDI ARABIA Saudi Arabia\' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators. Headline Expenditure Projections Pharmaceuticals: SAR16.70bn (US$4.46bn) in 2011 to SAR18.95bn (US$5.06bn) in 2012; +13.5% in local currency and US dollar terms. Forecastbroadly unchanged from Q3 12. Healthcare: SAR78.63bn (US$21.00bn) in 2011 to SAR91.20bn (US$24.35bn) in 2012; +16.0% in local currency and US dollar terms. Forecast broadly unchanged from Q3 12. Medicaldevices: SAR5.54bn (US$1.48bn) in 2011 to SAR6.53bn (US$1.74bn) in 2012; +17.8% in local currency and US dollar terms. Forecastunchanged from Q3 12. To Browse a Full Report with TOC @ http://www.resear

OVERVIEW OF THE PHARMACEUTICAL MARKET IN CZECH REPUBLIC The recent measures proposed by the Czech Republic\'s Ministry of Health will, in all likelihood, negatively affect the Czech pharmaceutical market. The introduction of reimbursement ceilings, blind bidding auctions and preferential prescribing will squeeze drugmakers\' margins and shift some of the burden of healthcare spending onto the private sector. The outcome of similar measures in Hungary and Poland strongly supports our view that the business environment for drugmakers will worsen if these proposals are adopted. It is patients who, ultimately, will suffer. Headline Expenditure Projections Pharmaceuticals: CZK80.71bn (US$4.56bn) in 2011 to CZK79.76bn (US$4.2bn) in 2012; -1.2% in local currency terms and -7.1% in US dollar terms. Healthcare: CZK298.49bn (US$16.88bn) in 2011 to CZK297.87bn (US$15.831bn) in 2012; +0.4% in local currency terms and -8.4% in US dollar terms. Medical Devices: CZK

OVERVIEW OF THE PHARMACEUTICAL MARKET IN DENMARK The macroenvironment for the Danish pharmaceutical industry is improving. The centre-left coalition, of the Social Democratic Party, the Socialist People\'s Party and the Social Liberal Party, took office in October 2011. Denmark suffered a deep recession and economic recovery is stalling with negative GDP growth projected for 2012. Denmark has an ageing population, and the Economist Intelligence Unit projects that the population aged 65 and over will constitute more than one-fifth of the total population by 2016. As a result, healthcare is increasingly focused on preventative care and there will be a continuing demand for new therapies so that patients can be treated more effectively. The increasing pharmaceutical expenditure in Denmark has led to price freezes and caps in recent years. A price ceiling, which has fixed pharmaceutical prices at the level they were five years ago, was extended to remain in place until the

OVERVIEW OF THE PHARMACEUTICAL MARKET IN VENEZUELA We expect the Venezuelan government to continue its foreign currency and import control policies in Q412 and the local market will endure further government restrictions on pharmaceutical and healthcare industry. Multinationals will have the potential revenue-generation opportunities from Venezuela\'s increasing reliance on imported products to meet local demand, as the election outcome will not fix the production capacity issues in the domestic industry. Headline Expenditure Projections Pharmaceuticals: VEB33.26bn (US$5.46bn) in 2011 to VEB40.77bn (US$6.00bn) in 2012; +22.6% in local currency terms and +10.0% in US dollar terms. Forecasts down due to new industrial information. Healthcare: VEB66.69bn (US$10.94bn) in 2011 to VEB83.29bn (US$12.26bn) in 2012; +24.9% in local currency terms and +12.0% in US dollar terms. Forecasts up due to new macro data. Medical devices: VEB9.62bn (US$1.58bn) in 2011 to VEB11.

2015 Global Automatic Palletizer Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Automatic Palletizer industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China). The report firstly introduced the Automatic Palletizer basics: definitions, classifications, applications and industry chain overview; To Browse a Full Report with TOC @ http://www.researchmoz.us/global-automatic-palletizer-industry-2015-trends-and-forecast-report-report.html industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis,

SUMMARY DelveInsights, 50S Ribosomal Subunit (50S RNA) Inhibitors -Pipeline Insights, 2016, report provides in depth insights on the pipeline drugs and their development activities around the 50S Ribosomal Subunit (50S RNA) Inhibitors. To Browse a Full Report with TOC @ http://www.researchmoz.us/50s-ribosomal-subunit-50s-rna-inhibitors-pipeline-insights-2016-report.html The DelveInsights Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsights Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for 50S Ribosomal Subunit (50S RNA) Inhibitors. DelveInsights Report also assesses the 50S R